Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for Metastatic Urothelial Carcinoma (first line)
(Pending Submission as of January 22, 2019)

Lenvatinib (Lenvima) for Advanced Renal Cell Carcinoma
(Notification to Implement Issued as of January 21, 2019)

Osimertinib (Tagrisso) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (first line) 
(Notification to Implement Issued as of January 21, 2019)

Bevacizumab (Mvasi) for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
(Final Biosimilar Dossier Issued as of January 14, 2019)

Pembrolizumab (Keytruda) for squamous Non-Small Cell Lung Cancer
(Pending Submission as of January 11, 2019)

Lenvatinib (Lenvima) for Hepatocellular Carcinoma
(Pending Submission as of January 3, 2019)

Trifluridine-Tipiracil (Lonsurf) for Metastatic Colorectal Cancer - Resubmission
(Pending Submission as of December 14, 2018)

Abiraterone (Zytiga) for Prostate Cancer
(Pending Submission as of November 27, 2018)

Find a Drug Review